KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBITDA (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed EBITDA for 4 consecutive years, with -$207.3 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, EBITDA fell 23.55% year-over-year to -$207.3 million, compared with a TTM value of -$888.8 million through Dec 2023, up 58.51%, and an annual FY2025 reading of -$309.1 million, up 43.83% over the prior year.
  • EBITDA was -$207.3 million for Q4 2023 at Ginkgo Bioworks Holdings, up from -$304.5 million in the prior quarter.
  • Across five years, EBITDA topped out at -$5.3 million in Q2 2021 and bottomed at -$1.7 billion in Q4 2021.
  • Average EBITDA over 4 years is -$353.6 million, with a median of -$188.5 million recorded in 2023.
  • Peak annual rise in EBITDA hit 90.35% in 2022, while the deepest fall reached 12096.98% in 2022.
  • Year by year, EBITDA stood at -$55.9 million in 2020, then crashed by 3012.24% to -$1.7 billion in 2021, then surged by 90.35% to -$167.8 million in 2022, then fell by 23.55% to -$207.3 million in 2023.
  • Business Quant data shows EBITDA for DNA at -$207.3 million in Q4 2023, -$304.5 million in Q3 2023, and -$173.0 million in Q2 2023.